Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Dimerix Ltd

DXB.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.21

▲ +0.00%

Market Cap $124.94M · Vol 1.86M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$124.94M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

72.73

Momentum

Beta

0.46

vs Market

52W High

$0.47

53.12% below

52W Low

$0.11

88.18% above

Volume

1.86M

Avg 1.70M

P/B

25.72

Price-to-book

ROE

N/A

Return on equity

Free Float

77.77%

Public shares

Shariah Compliance8 STANDARDS

✗ Dimerix Ltd (DXB.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DXB.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.27%

+22.92%

+34.09%

-37.89%

YTD

-46.36%

-37.23%

+343.37%

+27.75%

Financials & Valuation

TTM · Annual

Total Revenue	$3.89M
Net Income	$-8,719,614.00
Revenue Growth (YoY)	+385.34%
Gross Margin	100.00%
Operating Margin	-524.31%
Net Profit Margin	-224.08%
ROE	N/A
ROA · ROIC	-51.41% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	54.49
P/B	25.72
P/FCF	8.26
EPS Growth	N/A
Outstanding Shares	600.40M

Technical Indicators

50-Day SMA	$0.17
200-Day SMA	$0.26
RSI (14)	72.73
Beta	0.46
52-Week High	$0.47
52-Week Low	$0.11

Volume Today	1.86M
Avg Daily Volume (30D)	1.70M
Relative Volume	1.09x
Volatility (10D)	64.61
Volatility (30D)	68.87
Free Float	77.77%

Analyst Consensus

N/A

Current Price $0.21

Mean Target N/A

52W Low$0.11 52W High$0.47

Current

Target

$0.11 $0.47

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG001S9Z6Y8

ISINAU000000DXB7

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.